Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
NEW YORK and SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small
Assessing Zentalis Pharmaceuticals: A Balanced Hold Rating Amidst Financial Stability and Uncertain Market Prospects
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)
Buy Rating on Zentalis Pharmaceuticals Amid High Expectations for Azeno Drug Trials
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Zentalis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Zentalis Pharmaceuticals Price Target Cut to $40.00/Share From $46.00 by HC Wainwright & Co.
Zentalis Pharmaceuticals Price Target Cut to $40.00/Share From $46.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Zentalis Pharma, Lowers Price Target to $40
HC Wainwright & Co. analyst Andrew Fein maintains Zentalis Pharma with a Buy and lowers the price target from $46 to $40.
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
Zentalis Pharmaceuticals (ZNTL) has an average outperform rating and a price target range of $15 to $50, according to analysts polled by Capital IQ. Price: 12.06, Change: -0.25, Percent Change: -2.03
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) instance, it's good news for shareholders.
Zentalis Pharmaceuticals Is Maintained at Buy by Stifel
Zentalis Pharmaceuticals Is Maintained at Buy by Stifel
Zentalis Pharmaceuticals Price Target Cut to $32.00/Share From $36.00 by Stifel
Zentalis Pharmaceuticals Price Target Cut to $32.00/Share From $36.00 by Stifel
Stifel Maintains Buy on Zentalis Pharma, Lowers Price Target to $32
Stifel analyst Bradley Canino maintains Zentalis Pharma with a Buy and lowers the price target from $36 to $32.
Zentalis Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 159.95% Stifel $36 → $32 Maintains Buy 02/28/2024 273.68% HC Wainwright & Co. → $46 Reiterates
Express News | Zentalis Pharmaceuticals Inc : Stifel Cuts Target Price to $32 From $36
Buy Rating on Zentalis Pharmaceuticals: Strategic Developments and Multi-Cancer Treatment Potential of Azenosertib
Express News | Zentalis Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $40 From $46
Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts With Strategic ...
Express News | Zentalis Pharma's Q1 Cash, Cash Equivalents and Marketable Securities Position Of $489M Is Expected To Provide Cash Runway Into Mid-2026
Express News | Zentalis Pharma Q1 2024 GAAP EPS $0.14 May Not Be Comparable To $(0.73) Estimate, Sales $40.560M May Not Be Comparable To $13.125M Estimate